Entries by
Cardio quickPredict: A New Way to Evaluate Cardiotoxicity Potential [SOT 2018 – Presentation Slides]
Presented at the Society of Toxicology Annual Meeting and ToxEXPO in San Antonio, Texas, March 2018 by Stemina’s Associate Director of Toxicology, Jessica Palmer.Predicting cardiotoxicity remains a challenge. Cardiovascular toxicity is a major cause leading to compound attrition throughout the drug discovery and development process as well as withdrawal of FDA-approved drugs from the market…
Development of an In Vitro Assay to Predict Cardiotoxicity Potential Using Targeted Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [SOT 2018]
Presented at the Society of Toxicology Annual Meeting and ToxEXPO in San Antonio, Texas, March 2018, by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety-related withdrawals of FDA-approved drugs from the market. Metabolic perturbations are one of the primary mechanisms of cardiotoxicity elicited by pharmaceuticals…
Denise M. Ney, PhD, Registered Dietitian Nutritionist (RDN)
Professor of Nutritional Sciences, University of Wisconsin – Madison
Application of a Human Pluripotent Stem Cell-Based Assay for Developmental Toxicity Screening [Tox Forum 2018 – Presentation Slides]
Presented at The Toxicology Forum’s 42nd Annual Winter Meeting in Washington, DC in January 2018 by Stemina’s Associate Director of Toxicology, Jessica Palmer.
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) recently released the draft S5(R3) Guideline on Detection of Toxicity to Reproduction for Human Pharmaceuticals…
Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes [ACT 2017]
Presented at the American College of Toxicology’s 38th Annual Meeting in Palm Springs, California in November 2017 by Stemina’s Associate Director of Toxicology, Jessica Palmer.
Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of the safety related withdrawals of FDA-approved drugs from the market…
Stemina’s neurological disorders business unit has developed a test to aid in the earlier diagnosis of autism spectrum disorder.